Latest Partnerships News

Jameson Resources Limited has made significant progress in environmental approvals for its Crown Mountain Hard Coking Coal Project, while community and political backing for the coal sector in Canada strengthens. The company plans to resubmit its Environmental Impact Statement by mid-2025.

Equity Story Group Ltd (ASX:EQS) reports a robust December quarter marked by significant growth in funds under management, membership fees, and capital markets revenue, alongside strategic cost reductions positioning the company for sustained 2025 growth.

Codeifai Limited has terminated its exclusive licence with MIT and launched a strategic review of its material science division, signaling a decisive pivot towards digital and AI-driven brand solutions.

Avecho Biotechnology progresses its Phase III clinical trial for a TPM®-enhanced CBD insomnia capsule, expands patient recruitment, and completes a major manufacturing campaign for its U.S. partner Ashland.

BlinkLab has launched its pivotal FDA registrational study for its AI-driven autism diagnostic app, BlinkLab Dx 1, following positive FDA feedback and promising preliminary results.

Impact Minerals reports a maiden Measured Resource at its Lake Hope High Purity Alumina Project and secures $2.87 million in government funding to accelerate pilot plant development, while progressing exploration and IPO plans for other assets.

Dome Gold Mines reports steady progress on its Sigatoka industrial sand and magnetite project alongside securing a key government contract for emergency river desilting in Fiji. Exploration results also highlight promising copper and gold anomalies at its Nadroga tenement.

Firebird Metals Limited has secured preliminary design approval for its battery-grade manganese sulphate plant in China and forged a strategic partnership to develop LMFP cathode materials, marking significant progress in its EV battery ambitions.

NH3 Clean Energy has made significant strides in its WAH2 Project, finalising critical commercial agreements and progressing technical work ahead of Front End Engineering and Design (FEED) entry scheduled for Q1 2025. The company also completed a capital raise to support these developments.

Bluechiip Limited remains in ASX suspension as it finalises its 2024 audited accounts, while its ongoing Strategic Review and BioLife deal set the stage for a pivotal 2025 focused on revenue growth and cash-flow break-even.

Bluechiip Limited reported a $221,000 net cash outflow for Q2 FY2025, with cash reserves dwindling to $121,000. The company has initiated a strategic review and plans a capital raise to secure its future.

Bluechiip Limited advances its strategic repositioning with a new licensing agreement valued up to USD 750,000 alongside ongoing efforts to lift its trading suspension and grow sales.